Geographic Atrophy

Latest News

Needle and paperwork for clinical study Image credit: ©Scott Cornell - adobe.stock.com
Data and Safety Monitoring Board for Ocugen’s Phase 1/2 ArMaDa clinical approves medium dose of OCU410

April 11th 2024

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

Doctor consulting patient Image credit: Liudmmila Dutko - adobe.stock.com
Astellas receives permanent J-code for avacincaptad pegol intravitreal solution for GA

March 27th 2024

AMD screening Image credit: ©RFBSIP - adobe.stock.com
Study shows minocycline has no benefit in slowing, preventing GA expansion in patients with dry AMD

March 25th 2024

2024 on dice Image credit: ©Shutter2U - adobe.stock.com
Annexon outlines 2024 strategy for ANX007 for geographic atrophy

February 26th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.